Filtered By:
Condition: Antiphospholipid Syndrome
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 523 results found since Jan 2013.
Antiphospholipid Syndrome Diagnosed as a Result of the Occurrence of an Ischemic Stroke After a Successful Catheter Ablation of Atrial Fibrillation and Continuous Direct Oral Anticoagulants
We report a case of an ischemic stroke after a successful catheter ablation of atrial fibrillation (AF) and continuous oral anticoagulation therapy with direct oral anticoagulants (DOACs), which was the trigger for diagnosing antiphospholipid syndrome (APS). A 68-year-old woman underwent catheter ablation of persistent AF and continued oral anticoagulation with edoxaban at a dose of 30 mg once daily after the ablation procedure. An asymptomatic intracerebral hemorrhage was detected by brain computed tomography and magnetic resonance imaging one month post-ablation. Oral anticoagulation with dabigatran at 110 mg twice daily...
Source: International Heart Journal - January 31, 2022 Category: Cardiology Authors: Yumiko Haraguchi Kohki Nakamura Mitsuho Inoue Takehito Sasaki Kentaro Minami Shingo Yoshimura Shigeto Naito Source Type: research
Dabigatran in cardiovascular disease management: A comprehensive review
This article provides a comprehensive review on the role of dabigatran in various cardiovascular diseases.PMID:35070113 | PMC:PMC8716972 | DOI:10.4330/wjc.v13.i12.710
Source: World Journal of Cardiology - January 24, 2022 Category: Cardiology Authors: Ayesha Javed Muhammad Ajmal Aaron Wolfson Source Type: research
Antiphospholipid syndrome-mediated acute cerebrovascular diseases and long-term outcomes
CONCLUSION: We found no differences between stroke subtypes and APS types. aPL profiles were not associated with any of the acute cerebrovascular diseases described in this cohort. CVT may be an initial thrombotic manifestation of APS with low mortality and good long-term functional outcome.PMID:35042376 | DOI:10.1177/09612033221074178
Source: Lupus - January 19, 2022 Category: Rheumatology Authors: Miguel Garc ía-Grimshaw Diego Rub én Posadas-Pinto Amado Jim énez-Ruiz Sergio Iv án Valdés-Ferrer Arturo Cadena-Fern ández Jos é Jiram Torres-Ruiz Jos é Domingo Barrientos-Guerra Margarita Amancha-Gabela Erwin Chiquete Fernando Daniel Flores-Silva Source Type: research
Was Antiphospholipid Syndrome a Risk Factor of Stroke? A Systemic Review and Meta-Analysis of Cohort Studies
Dis Markers. 2021 Dec 16;2021:4431907. doi: 10.1155/2021/4431907. eCollection 2021.ABSTRACTAntiphospholipid syndrome (APS) is characterized by thrombosis. This systemic review and meta-analysis was to verify the hypothesis that APS might increase the risk of stroke. Studies were identified after literature searching of PubMed, Embase, and Cochrane. Newcastle-Ottawa Quality Assessment Scale Cohort Studies (NOQAS-C) was used to assess the quality of studies. The pooled effect with 95% confidence interval (95% CI) was calculated by random-effect model. I-square (I 2) was used to test heterogeneity. Funnel plot was used to eva...
Source: Disease Markers - December 27, 2021 Category: Laboratory Medicine Authors: Kai Zhao Ping Zhou Ling Xu Ruili Li Jincai Yang Qiang Zhang Mingfei Yang Xiaoxing Wei Source Type: research
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
